Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis.

Guo H, Guo Q, Li Z, Wang Z

Frontiers in pharmacology13 Nov 2024Cited by 22 (Europe PMC)

PMID39605914PMCIDPMC11600108DOI10.3389/fphar.2024.1461398PepBankPUB-39605914

Summary

ObjectiveGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown notable advancements in managing blood sugar control. Nevertheless, there remains a gap in real-world data regarding the variation in acute pancreatitis (AP) risk among different GLP-1 RAs. Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.MethodsWe described a case series of patients experiencing AP while on GLP-1 RAs. Additionally, we utilized various algorithms including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) to analyze data from the Food and Drug Administration's Adverse Event Reporting System (FAERS) regarding suspected adverse events of AP linked to GLP-1 RAs from January 2005 to September 2023.ResultsOur case series comprised thirty-nine patients who experienced AP events while on GLP-1 RAs. Within the FAERS database, we retrieved a total of 6,751 individual case safety reports (ICSRs) involving various GLP-1 RAs. The median age of the patients included in our study was 57 years (range: 14-99), with 98.3% of cases classified as serious. Signals indicating AP were observed across all GLP-1 RAs, with particular emphasis on exenatide and liraglutide.ConclusionThere is a notable reporting signal of AP associated with all GLP-1 RAs. Healthcare providers must remain vigilant and closely monitor this potentially life-threatening adverse event.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study12

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studySafety outcome
In FAERS, liraglutide showed a particularly emphasized acute pancreatitis reporting signal.
In plain wordsIn adverse-event records, liraglutide was linked to a particularly emphasized pancreatitis reporting signal.
Peptide
Liraglutide
Outcome
IncreaseAcute pancreatitis reporting signal
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Signals indicating AP were observed across all GLP-1 RAs, with particular emphasis on exenatide and liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Additionally, we utilized various algorithms including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) to analyze data from the Food and Drug Administration's Adverse Event Reporting System (FAERS)
Show in the study text Report a problemFND-3960591410
02HumanObservational studySafety outcome
In FAERS, semaglutide showed an acute pancreatitis reporting signal, as did all evaluated GLP-1 receptor agonists.
In plain wordsIn adverse-event records, semaglutide was linked to a pancreatitis reporting signal, as were all evaluated GLP-1 drugs.
Peptide
Semaglutide
Outcome
IncreaseAcute pancreatitis reporting signal
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Signals indicating AP were observed across all GLP-1 RAs, with particular emphasis on exenatide and liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.
Summary · context
Additionally, we utilized various algorithms including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) to analyze data from the Food and Drug Administration's Adverse Event Reporting System (FAERS)
Show in the study text Report a problemFND-3960591411
03HumanObservational studySafety outcome
In FAERS, tirzepatide showed an acute pancreatitis reporting signal, as did all evaluated GLP-1 receptor agonists.
In plain wordsIn adverse-event records, tirzepatide was linked to a pancreatitis reporting signal, as were all evaluated GLP-1 drugs.
Peptide
Tirzepatide
Outcome
IncreaseAcute pancreatitis reporting signal
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Signals indicating AP were observed across all GLP-1 RAs, with particular emphasis on exenatide and liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.
Summary · context
Additionally, we utilized various algorithms including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) to analyze data from the Food and Drug Administration's Adverse Event Reporting System (FAERS)
Show in the study text Report a problemFND-3960591412

Studies that did not test the peptide alone9

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
Among pooled GLP-1 receptor agonist pancreatitis reports, including dulaglutide, 98.3% were serious.
In plain wordsAmong pooled pancreatitis reports for GLP-1 drugs, including dulaglutide, 98.3% were serious.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSerious pancreatitis reports in pooled class
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Measurements
Cases classified as serious
98.3%
pooled GLP-1 RA acute pancreatitis cases
Source sentences
Summary
The median age of the patients included in our study was 57 years (range: 14-99), with 98.3% of cases classified as serious.
3 context sentences(design, population, supporting numbers)
Summary · context
Within the FAERS database, we retrieved a total of 6,751 individual case safety reports (ICSRs) involving various GLP-1 RAs.
Summary · context
Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.
Summary · context
Additionally, we utilized various algorithms including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) to analyze data from the Food and Drug Administration's Adverse Event Reporting System (FAERS)
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3960591405
05HumanNot a test of Liraglutide aloneObservational studySafety outcome
Among pooled GLP-1 receptor agonist pancreatitis reports, including liraglutide, 98.3% were serious.
In plain wordsAmong pooled pancreatitis reports for GLP-1 drugs, including liraglutide, 98.3% were serious.
Peptide
Liraglutide
Outcome
Not applicableSerious pancreatitis reports in pooled class
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Measurements
Cases classified as serious
98.3%
pooled GLP-1 RA acute pancreatitis cases
Source sentences
Summary
The median age of the patients included in our study was 57 years (range: 14-99), with 98.3% of cases classified as serious.
3 context sentences(design, population, supporting numbers)
Summary · context
Within the FAERS database, we retrieved a total of 6,751 individual case safety reports (ICSRs) involving various GLP-1 RAs.
Summary · context
Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.
Summary · context
Additionally, we utilized various algorithms including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) to analyze data from the Food and Drug Administration's Adverse Event Reporting System (FAERS)
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3960591406
06HumanNot a test of Semaglutide aloneObservational studySafety outcome
Among pooled GLP-1 receptor agonist pancreatitis reports, including semaglutide, 98.3% were serious.
In plain wordsAmong pooled pancreatitis reports for GLP-1 drugs, including semaglutide, 98.3% were serious.
Peptide
Semaglutide
Outcome
Not applicableSerious pancreatitis reports in pooled class
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Measurements
Cases classified as serious
98.3%
pooled GLP-1 RA acute pancreatitis cases
Source sentences
Summary
The median age of the patients included in our study was 57 years (range: 14-99), with 98.3% of cases classified as serious.
3 context sentences(design, population, supporting numbers)
Summary · context
Within the FAERS database, we retrieved a total of 6,751 individual case safety reports (ICSRs) involving various GLP-1 RAs.
Summary · context
Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.
Summary · context
Additionally, we utilized various algorithms including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) to analyze data from the Food and Drug Administration's Adverse Event Reporting System (FAERS)
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3960591407
07HumanNot a test of Tirzepatide aloneObservational studySafety outcome
Among pooled GLP-1 receptor agonist pancreatitis reports, including tirzepatide, 98.3% were serious.
In plain wordsAmong pooled pancreatitis reports for GLP-1 drugs, including tirzepatide, 98.3% were serious.
Peptide
Tirzepatide
Outcome
Not applicableSerious pancreatitis reports in pooled class
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Measurements
Cases classified as serious
98.3%
pooled GLP-1 RA acute pancreatitis cases
Source sentences
Summary
The median age of the patients included in our study was 57 years (range: 14-99), with 98.3% of cases classified as serious.
3 context sentences(design, population, supporting numbers)
Summary · context
Within the FAERS database, we retrieved a total of 6,751 individual case safety reports (ICSRs) involving various GLP-1 RAs.
Summary · context
Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.
Summary · context
Additionally, we utilized various algorithms including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) to analyze data from the Food and Drug Administration's Adverse Event Reporting System (FAERS)
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-3960591408
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In FAERS, an acute pancreatitis reporting signal was observed across all evaluated GLP-1 receptor agonists, a class including dulaglutide.
In plain wordsIn adverse-event reports, a pancreatitis reporting signal was seen across all evaluated GLP-1 drugs, a group that includes dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAcute pancreatitis reporting signal
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Signals indicating AP were observed across all GLP-1 RAs, with particular emphasis on exenatide and liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.
Summary · context
Additionally, we utilized various algorithms including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) to analyze data from the Food and Drug Administration's Adverse Event Reporting System (FAERS)
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3960591409
09HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesSafety outcome
A case series reported acute pancreatitis in GLP-1 receptor agonist users, a class including dulaglutide.
In plain wordsA case series reported pancreatitis in users of GLP-1 drugs, a class including dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAcute pancreatitis case series
Study
n = 39
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Our case series comprised thirty-nine patients who experienced AP events while on GLP-1 RAs.
2 context sentences(design, population, supporting numbers)
Summary · context
Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.
Summary · context
We described a case series of patients experiencing AP while on GLP-1 RAs.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3960591401
10HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome
A case series reported acute pancreatitis in GLP-1 receptor agonist users, a class including liraglutide.
In plain wordsA case series reported pancreatitis in users of GLP-1 drugs, a class including liraglutide.
Peptide
Liraglutide
Outcome
Not applicableAcute pancreatitis case series
Study
n = 39
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Our case series comprised thirty-nine patients who experienced AP events while on GLP-1 RAs.
2 context sentences(design, population, supporting numbers)
Summary · context
Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.
Summary · context
We described a case series of patients experiencing AP while on GLP-1 RAs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3960591402
11HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome
A case series reported acute pancreatitis in GLP-1 receptor agonist users, a class including semaglutide.
In plain wordsA case series reported pancreatitis in users of GLP-1 drugs, a class including semaglutide.
Peptide
Semaglutide
Outcome
Not applicableAcute pancreatitis case series
Study
n = 39
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Our case series comprised thirty-nine patients who experienced AP events while on GLP-1 RAs.
2 context sentences(design, population, supporting numbers)
Summary · context
Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.
Summary · context
We described a case series of patients experiencing AP while on GLP-1 RAs.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-3960591403
12HumanNot a test of Tirzepatide aloneCase report or seriesSafety outcome
A case series reported acute pancreatitis in GLP-1 receptor agonist users, a class including tirzepatide.
In plain wordsA case series reported pancreatitis in users of GLP-1 drugs, a class including tirzepatide.
Peptide
Tirzepatide
Outcome
Not applicableAcute pancreatitis case series
Study
n = 39
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
Our case series comprised thirty-nine patients who experienced AP events while on GLP-1 RAs.
2 context sentences(design, population, supporting numbers)
Summary · context
Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports.
Summary · context
We described a case series of patients experiencing AP while on GLP-1 RAs.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-3960591404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 6Current
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 5
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 4
21 Oct 2026, 18:59 UTC
The same notice was added 3 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis.

Summary

Results from this study12

Studies that did not test the peptide alone9

Version history

Subjects

Publication types

Keywords